Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628787 | 0.83 | POLB (0.40) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL16628788 | 0.83 | POLB (0.40) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL2843887 | 0.83 | POLB (0.37) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL2843889 | 0.83 | POLB (0.37) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL6760115 | 0.83 | POLB (0.37) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL8238400 | 0.83 | POLB (0.37) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL14020643 | 0.80 | POLB (0.38) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 | |
| SCHEMBL8003568 | 0.80 | CTSB (0.35) | CTSBCTSS | |
| SCHEMBL312570 | 0.80 | CTSB (0.35) | CTSBCTSS | |
| SCHEMBL12730845 | 0.77 | SMN1; SMN2 (0.37) | POLBSMN1; SMN2MAPTALDH1A1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| EP-2803658-A1 | Phosphinate ruthenium complexes | IDENIX Pharmaceuticals, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8765966-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2013-10-10 | — | — | US | disclosed |
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8481748-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8410313-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309737-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | POLB 282/4885SMN1; SMN2 4181/4885MAPT 3447/4885 |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | POLB 4050/4885SMN1; SMN2 2582/4885MAPT 3005/4885 |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | POLB 282/4885SMN1; SMN2 4181/4885MAPT 3447/4885 |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | POLB 282/4885SMN1; SMN2 4181/4885MAPT 3447/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | POLB 4050/4885SMN1; SMN2 2582/4885MAPT 3005/4885 |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, PHOSPHO1 | POLB 230/4885SMN1; SMN2 4274/4885MAPT 3415/4885 |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | POLB 282/4885SMN1; SMN2 4181/4885MAPT 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.